Dr O’Donoghue discusses preliminary results from the CANTOS trial of canakinumab, a unique anti-inflammatory agent which represents a new pathway for treating cardiovascular disease.

Behavior counseling in type 2 diabetes, FDA regulation of tobacco, cuff BP readings, smoking cessation, and CV genetics are discussed this week.

Eric Topol speaks with Sekar Kathiresan about cardiovascular genomics, why 'DNA isn't destiny,' and why we still have heart attacks in spite of statins.

Obstructive sleep apnea, changes in diet, AF ablation, statin rechallenge, and prediabetes are covered in this week's podcast.

Dr Califf talks about his new role at Verily and how data mining and data sharing could reduce disparities in care and improve patient outcomes.

Dr Piña runs through some of the key takeaways from the ACC/AHA/HFSA Focused Update of the guidelines on the management of heart failure.

Declining rates of sudden death in patients with heart failure, a new indication for TAVR, coffee (again), and counseling the well are the topics discussed by Dr Mandrola in this week’s podcast.

What is the latest on fish oil supplementation for cardiovascular disease prevention? Dr Manson reviews a new science advisory from the American Heart Association.

From being critiqued by Bernie Sanders to the controversial Duchenne drug approval decision, Dr Califf recounts his experiences as FDA commissioner.

Cardiac tests after ED visits, specialist vs generalist care for AF, leadless pacing, anacetrapib for HDL raising, and pragmatic research trials are discussed by Dr Mandrola in this week's podcast.